Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 28 for “"Non-Alcoholic Steatohepatitis (NASH)"”.
-
The role of "non-alcoholic steatohepatitis (NASH)" in methotrexate induced liver injury
… for psoriasis. The histological features are nonspecific and may resemble those of nonalcoholic steatohepatitis (NASH). Moreover most of the risk factors of MTX induced liver injury are also associated with NASH. In this study serial liver biopsies of 24 psoriatic patients on lOng-term MTX …
-
DEVELOPMENT OF IN VITRO NON-ALCOHOLIC STEATOHEPATITIS (NASH) MODEL FOR DRUG TESTING AND PATHOGENESIS STUDIES
Non-alcoholic steatohepatitis (NASH) is a severe chronic fatty liver disease that currently has no effective intervention. Hepatocellular ballooning is one of the key features of NASH diagnosis. Due to their scarcity, it is difficult to study in vivo and isolate for in vitro investigations. How …
-
Diversified use of Non-invasive Biomarkers in Study Protocol and Screen failure in Non-Alcoholic Steatohepatitis (NASH)
This study examines how non-invasive biomarkers of NASH are introduced into the study protocol and whether this has an impact on screen failure. The study will investigate the use of non-invasive biomarkers in the design of study protocols for NASH drug trials and will also examine if screening …
-
Effect of Delta-Tocotrienol and Grape Seed Polyphenol on Lipid Profile in C57BL/6J Mice with a Western-Like Diet-Included Non-Alcoholic Steatohepatitis
Non-alcoholic steatohepatitis (NASH), the second phase in liver disease, occurs when adults consume high calorie, high fat diets. Fat accumulated in the liver causes inflammation and irreversible hardening. Grape seed polyphenol (GSP) and d-tocotrienol (d-T3) may have benefits in reducing NASH. We …
-
Using Telemedicine To Optimize The Delivery Of Care In Patients With Liver Disease
… globally. Among the spectrum of liver diseases, non-alcoholic steatohepatitis (NASH) is the most common cause of cirrhosis and one of the top reasons for a liver transplant. Patients with NASH end up with hepatic decompensation and liver-related complications such as malnutrition, sarcopenia, …
-
Role of Ceramidase in Regulating Hepatic Lipid Metabolism and Whole Body Insulin Sensitivity
… with the rise in obesity, the prevalence of non-alcoholic fatty liver disease (NAFLD), a newly emerging obesity-related disorder, has also been rising steadily. NAFLD is a chronic liver disease that ranges histologically from simple steatosis in its mildest form to non-alcoholic …
-
The db mouse as a model for steatohepatitis
… of the liver to an inflammatory condition, steatohepatitis, which may lead onto cirrhosis. Although not associated with alcohol consumption, non-alcoholic steatohepatitis (NASH) has strong associations with obesity, diabetes and dyslipidaemia. Overlapping pathological mechanisms may be …
-
Molecular and systems-level analyses reveal the emerging role of non-coding RNAs in liver diseases
… body. Thus, the liver is prone to many diseases. Non-alcoholic fatty liver disease (NAFLD), the most common liver disease, is an umbrella term for a range of conditions compromising hepatic steatosis, non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis without alcohol consumption, which …
-
Surface Modifications of Iron Oxide Nanoparticles for Magnetic Imaging and Diagnosis
… of colloidal iron oxide nanoparticles as non-toxic MRI contrast agents for diagnosis. Novel single-nanometer iron oxide (SNIO) nanoparticles exhibited contrast enhancement in T1-weighted MRI superior than commercially used gadolinium-based contrast agents, with unprecedentedly fast and …
-
Engineering in vitro models of non-alcoholic fatty liver disease
… rates throughout the world. Consequentially, non-alcoholic fatty liver disease (NAFLD), which is highly correlated with obesity, rates are also increasing with greater than 30% of the US population currently diagnosed. NAFLD starts as a benign state of fat accumulation within liver hepatocytes …
-
Investigating the role of transcription factor Nrf2 in the pathogenesis of NAFLD
The pathogenesis of non-alcoholic steatohepatitis (NASH) is thought to occur through interacting mechanisms of cellular stress. Lipids accumulate within hepatocytes, making cells more susceptible to insult and less able to respond to challenges, leading to progression from simple steatosis to …
-
The unfolded protein response regulates hepatocellular injury during the pathogenesis of nonalcoholic steatohepatitis
Non-alcoholic steatohepatitis (NASH), which is characterized by the induction of hepatocellular death and inflammation, is associated with the activation of cellular stress pathways such as the Unfolded Protein Response (UPR), an adaptive response to disruptions in endoplasmic reticulum (ER) …
-
The Role and Regulation of Caspase-2 in Lipoapoptosis
<p>Non-alcoholic fatty liver disease (NAFLD) is now the most common liver disorder in Western countries. NAFLD is characterized by hepatic steatosis, or an intracellular accumulation of lipids in hepatocytes. An excess of intracellular lipids can cause toxicity, leading to hepatocyte cell death and …
-
Hepatoprotective properties of Gentiana SPP: Against non-alcoholic fatty liver disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD) is a metabolic disease characterised by the accumulation of fat in the liver. It is estimated that 33 % of the UK population have NAFLD with 2-5 % progressing to non-alcoholic steatohepatitis (NASH). Due to a lack of an outright therapy for NAFLD, treatment …
-
Non-invasive diagnosis of non-alcoholic fatty liver disease.
Non-alcoholic fatty liver disease (NAFLD) has become one of the top concerns for the practising hepato-gastroenterologist due to the obesity epidemic and its potential to progress to an advanced liver disease that significantly impacts on overall and liver-related mortality. Due to the rapidly …
-
Diabetes and obesity as risk factors for the development of Hepatocellular carcinoma in the hispanic population
… a 2.7 times higher risk for HCC development than non-Hispanic whites and the highest mortality rate next to Asian population. The reason for this increased HCC risk in Hispanics is unknown. While it is conceivable that this disparity could be secondary to the incidence of hepatitis or alcohol …
-
CODING E NON-CODING RNA COME BIOMARCATORI DI SEVERITA’ DI NAFLD E DI FIBROSI
La steatosi epatica non alcolica (Non-Alcoholic Fatty Liver Disease, NAFLD) è l’epatopatia cronica più comune nei paesi industrializzati con una prevalenza del 20-30% nella popolazione generale. La NAFLD comprende un vasto spettro di patologie epatiche e sebbene sia generalmente considerata una …
-
Targeting LGALS3 to treat steatotic liver disease and hepatocarcinogenesis
Non-alcoholic fatty liver disease (NAFLD), recently renamed as Metabolic dysfunction-associated steatotic liver disease (MASLD), is the leading cause of chronic liver disease (CLD) and liver-related morbidity and mortality worldwide. NAFLD, characterized by hepatic fat accumulation and coexisting …
-
INDUCED PLURIPOTENT STEM CELL DERIVED LIVER MODEL FOR THE STUDY OF PNPLA3-ASSOCIATED NON-ALCOHOLIC FATTY LIVER DISEASE
Non-alcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease in the developed world, afflicting approximately one in four adults globally. NAFLD is defined by the accumulation of fat within the liver which ranges in severity from simple steatosis to non-alcoholic …
Page 1 of 2